Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.

Infante JR, Bendell JC, Goff LW, Jones SF, Chan E, Sudo T, Burris HA, Berlin JD
Eur J Cancer. 2013 49 (6): 1169-75

PMID: 23294608 · DOI:10.1016/j.ejca.2012.11.033

PURPOSE - The objective of this first-in-human trial included the safety, maximum tolerated dose (MTD), pharmacokinetics, immunogenicity and antitumour effects of KRN330, a novel fully-human monoclonal antibody directed against A33, a membrane bound glycoprotein uniformly expressed in 95% of colorectal cancers.

METHODS - Patients with advanced or metastatic colorectal cancer (CRC) refractory to standard therapy were eligible. Twenty-nine patients received weekly intravenous KRN330 (0.1-10mg/kg) for a minimum of 4 weeks in a standard 3+3 design, and nine patients received q2 week doses at 3mg/kg with pre- and post-biopsies to evaluate tumour binding and safety on this schedule.

RESULTS - The most common KRN330 related adverse events (all grades) were nausea (66%), diarrhoea (61%) and vomiting (47%). The MTD was 3mg/kg weekly, with dose-limiting grade 3 gastrointestinal toxicities at 10mg/kg and the intermediate dose level of 6 mg/kg. Pharmacokinetics of KRN330 was linear. Stable disease was reported in 12/38 patients (32%), with a median duration of 155 days. There was no evidence of human anti-human antibodies, and immunohistochemistry on biopsy samples demonstrated that KRN330 remained bound to tumour 2 weeks after dosing.

CONCLUSIONS - KRN330 is safe and tolerable at the MTD of 3mg/kg once weekly in patients with advanced CRC. Dosing on alternate weeks is supported by tumour binding. The long treatment durations and lack of immunogenicity warrant further investigation of KRN330 in combination.

Copyright © 2012 Elsevier Ltd. All rights reserved.

MeSH Terms (22)

Adult Aged Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Area Under Curve Colorectal Neoplasms Diarrhea Dose-Response Relationship, Drug Drug Administration Schedule Drug Resistance, Neoplasm Female Humans Immunohistochemistry Male Membrane Glycoproteins Metabolic Clearance Rate Middle Aged Nausea Neoplasm Metastasis Time Factors Treatment Outcome Vomiting

Connections (2)

This publication is referenced by other Labnodes entities: